Tracer library / [177Lu]Lu-girentuximab

[177Lu]Lu-girentuximab

Also written as [Lu-177]Lu-girentuximab

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Gastrointestinal and colorectal cancer

What it is

Compound class: Anti-CA-IX monoclonal antibody (DOTA-conjugated girentuximab)
Target / mechanism: Carbonic Anhydrase IX (CA-IX) PMID 40227816
Clinical application: Non-muscle-invasive bladder cancer (NMIBC) unresponsive to standard of care PMID 40227816
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>95%	>95%	DOTA-Girentuximab	41631002 2026 Gastro Hep Adv [177Lu]LuCl3 (900 MBq) in HCl (110 μL, 0.05 M) was neutralized with ammonium acetate solution (1 M, pH 6–7) then DOTA-Girentuximab (1.8 mg) was added. - Aliquot was analyzed and found to have a radiochemical yield of >95% with >95% radiochemical purity.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [211At]At-anti-CA-IX Antibody (ATO-101™) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care.
2025 · Cancers (Basel) · Clinical study

Need this precursor?We can point you to suppliers for [177Lu]Lu-girentuximab, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41631002: 'DOTA-Girentuximab'. Stage set/updated at stage 39 from PMID 40227816: 'The anti-CA-IX antibody, girentuximab (TLX250), was labeled with lutetium-177 and astatine-211 for in vitro studies.'.